MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, COLL made $193,520K in revenue. $14,496K in net income. Net profit margin of 7.49%.

Income Overview

Revenue
$193,520K
Net Income
$14,496K
Net Profit Margin
7.49%
EPS
$0.4
Unit: Thousand (K) dollars
Revenue Breakdown
    • Belbuca
    • Xtampza ER
    • Jornay Pm
    • Others

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Product revenues, net
193,520 205,449 209,361 188,000
Intangible asset amortization and impairment
--55,473 55,473
Cost of product revenues (excluding intangible asset amortization)
20,801 21,598 24,717 24,143
Intangible asset amortization
55,473 55,473 --
Total cost of product revenues
76,274 77,071 80,190 79,616
Gross profit
117,246 128,378 129,171 108,384
Selling, general and administrative
86,350 67,640 67,103 73,637
Gain on fair value remeasurement of contingent consideration
0 -19 -19 -358
Total operating expenses
86,350 67,621 67,084 73,279
Income from operations
30,896 60,757 62,087 35,105
Interest income
--3,116 2,383
Interest expense
15,862 19,292 21,767 20,463
Interest income
3,706 2,822* --
Loss on extinguishment of debt
--15,251* --
Income before income taxes
18,740 29,036 43,436 17,025
Provision for income taxes
4,244 12,073 11,929 5,042
Net income
14,496 16,963 31,507 11,983
Basic EPS
0.45 0.536 1 0.38
Diluted EPS
0.4 0.357 0.84 0.34
Basic Average Shares
32,087,472 31,649,955 31,571,410 31,810,612
Diluted Average Shares
40,065,665 47,451,026 39,439,890 39,075,703
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Belbuca$52,649K (1.92%↑ Y/Y)Xtampza ER$50,769K Jornay Pm$38,893K (36.28%↑ Y/Y)Nucynta IR$26,078K Nucynta ER$18,233K Symproic$4,194K (48.99%↑ Y/Y)Nucynta ERAG$1,446K Nucynta IRAG$1,258K Product revenues, net$193,520K (8.87%↑ Y/Y)Gross profit$117,246K (20.47%↑ Y/Y)Total cost of productrevenues$76,274K (-5.17%↓ Y/Y)Income from operations$30,896K (42.46%↑ Y/Y)Interest income$3,706K (66.56%↑ Y/Y)Total operatingexpenses$86,350K (14.16%↑ Y/Y)Intangible assetamortization$55,473K (0.00%↑ Y/Y)Cost of productrevenues (excluding...$20,801K (-16.66%↓ Y/Y)Income before incometaxes$18,740K (500.26%↑ Y/Y)Interest expense$15,862K (-23.70%↓ Y/Y)Selling, general andadministrative$86,350K (12.99%↑ Y/Y)Net income$14,496K (499.75%↑ Y/Y)Provision for income taxes$4,244K (501.99%↑ Y/Y)

COLLEGIUM PHARMACEUTICAL, INC (COLL)

COLLEGIUM PHARMACEUTICAL, INC (COLL)